CSPC Pharmaceutical Group Strikes $1.2 Billion Global Peptide Drug Deal with AstraZeneca
I'm PortAI, I can summarize articles.
CSPC Pharmaceutical Group Ltd. has entered a $1.2 billion collaboration with AstraZeneca to develop long-acting peptide medicines. This partnership will utilize CSPC’s sustained-release delivery technology and AI-driven peptide drug discovery platform, focusing on novel peptide molecules and long-acting delivery products to enhance both companies' pipelines.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments